tiprankstipranks
Trending News
More News >
Clearside Biomedical Inc (CLSD)
:CLSD

Clearside Biomedical (CLSD) AI Stock Analysis

Compare
1,020 Followers

Top Page

CL

Clearside Biomedical

(NASDAQ:CLSD)

Rating:44Neutral
Price Target:
$1.00
▲(23.46%Upside)
The overall stock score is primarily impacted by Clearside Biomedical's poor financial performance, characterized by declining revenues, ongoing losses, and a weak balance sheet. Limited technical momentum and a negative valuation further weigh on the score, indicating high financial risk and limited attractiveness to investors.
Positive Factors
Product Differentiation
The key differentiator for CLS-AX is its flexible dosing schedule for every 3 to 6 months based on disease activity.
Regulatory Progress
Arctic Vision's New Drug Application for ARCATUS was accepted for review in China and approved in Australia and Singapore for the treatment of uveitic macular edema.
Valuation
CLSD is trading at a heavy discount compared to peers despite having a competitive Phase 3 ready asset.
Negative Factors
Capital Requirements
Clearside Biomedical Inc. needs to secure additional financing or enter into a partnership to advance the proposed phase 3 program.
Financial Performance
Net loss totaled $8.2M in search of funding for Phase 3 wet AMD program.
Investment Needs
The phase 3 trials are expected to require significant investment and could take 2 to 3 years to report results.

Clearside Biomedical (CLSD) vs. SPDR S&P 500 ETF (SPY)

Clearside Biomedical Business Overview & Revenue Model

Company DescriptionClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
How the Company Makes MoneyClearside Biomedical makes money primarily through the development and potential commercialization of its proprietary therapies for eye diseases. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with pharmaceutical companies. These partnerships often involve Clearside providing its SCS Microinjector™ technology to facilitate drug delivery. Additionally, the company may earn revenue from the eventual sale of approved therapies derived from its product pipeline, as well as from potential royalties on sales of partnered products.

Clearside Biomedical Earnings Call Summary

Earnings Call Date:May 14, 2025
(Q4-2024)
|
% Change Since: -4.71%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.
Q4-2024 Updates
Positive Updates
Positive Results from ODYSSEY Phase 2b Trial
Clearside's ODYSSEY Phase 2b wet AMD clinical trial showed positive results, leading to a successful end of Phase 2 meeting with the FDA. The company is aligned on a pivotal Phase 3 program for CLS-AX, setting it up for potential commercial success.
Regulatory Progress and Partnerships in Asia-Pacific
Arctic Vision achieved several regulatory milestones in the Asia-Pacific region with ARCATUS/XIPERE, including approval in Australia and Singapore and a new drug application under review in China. A commercial collaboration with Santen Pharmaceuticals was also established.
Strong Financial Position
As of December 31, 2024, the company had cash and cash equivalents totaling approximately $20 million, with resources to fund operations into the fourth quarter of 2025.
Negative Updates
Funding Required for Phase 3 Program
Clearside is actively pursuing options to fund the CLS-AX Phase 3 program, indicating the need for additional financial resources or partnerships to commence the trial.
Potential Enrollment Challenges
The Phase 3 trial design for CLS-AX includes specific criteria that may exclude patients with high variability, which might affect enrollment speed.
Company Guidance
During the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call, the company provided detailed guidance on its Phase 3 plans for the CLS-AX treatment for wet AMD. The pivotal Phase 3 program will consist of two non-inferiority trials, aiming to enroll treatment-naive patients, with a planned duration of enrollment of around 12 months. The design includes a personalized treatment interval (PTI) assessment at weeks 12, 16, and 20 to determine dosing regimens of every 12, 16, 20, or 24 weeks. The trials will use advanced OCT biomarkers to guide redosing, with an emphasis on reducing variability by excluding participants with significant non-disease-related visual acuity changes prior to randomization. The total cost of the trials is estimated at $55-$60 million each, with Clearside actively exploring funding options, including potential partnerships. The company also highlighted its strategic focus on suprachoroidal delivery, with ongoing collaborations and a robust pipeline, despite reporting cash and cash equivalents of approximately $20 million as of December 31, 2024.

Clearside Biomedical Financial Statement Overview

Summary
Clearside Biomedical's financials demonstrate significant challenges, including declining revenues leading to zero, persistent losses, negative stockholders' equity, and negative free cash flow. The company's reliance on external financing, coupled with high liabilities and leverage risks, presents substantial financial instability.
Income Statement
25
Negative
The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.
Balance Sheet
20
Very Negative
The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.
Cash Flow
30
Negative
The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.76M1.66M8.23M1.33M29.57M7.89M
Gross Profit3.37M1.51M7.87M1.12M29.40M7.89M
EBITDA-19.76M-24.35M-23.06M-29.46M-449.00K-17.93M
Net Income-30.81M-34.35M-32.48M-34.07M376.00K-18.03M
Balance Sheet
Total Assets19.67M25.13M34.02M51.30M42.90M19.32M
Cash, Cash Equivalents and Short-Term Investments13.63M20.02M28.92M48.26M30.44M17.29M
Total Debt619.00K703.00K43.00M1.28M675.00K1.98M
Total Liabilities65.58M63.98M49.93M40.70M4.93M10.56M
Stockholders Equity-45.91M-38.85M-15.91M10.61M37.98M8.76M
Cash Flow
Free Cash Flow-23.60M-25.68M-19.91M-13.61M-10.73M-13.18M
Operating Cash Flow-22.68M-24.70M-18.14M-13.37M-10.73M-13.12M
Investing Cash Flow-590.00K-638.00K-1.78M-246.00K0.00-55.00K
Financing Cash Flow1.54M16.44M414.00K31.33M23.78M7.87M

Clearside Biomedical Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.81
Price Trends
50DMA
0.82
Negative
100DMA
0.87
Negative
200DMA
0.97
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
50.14
Neutral
STOCH
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Neutral. The current price of 0.81 is above the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.82, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLSD.

Clearside Biomedical Risk Analysis

Clearside Biomedical disclosed 69 risk factors in its most recent earnings report. Clearside Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clearside Biomedical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
44
Neutral
$63.12M91.63%-55.47%24.92%
44
Neutral
$87.15M-55.14%-99.43%-69.40%
44
Neutral
$88.18M-122.69%20.91%
40
Neutral
$47.63M-127.99%37.54%
37
Underperform
$258.25M-141.69%-17.06%
35
Underperform
$101.70M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLSD
Clearside Biomedical
0.81
-0.44
-35.20%
ADVM
Adverum Biotechnologies
2.28
-4.90
-68.25%
JSPR
Jasper Therapeutics
6.77
-14.35
-67.95%
INZY
Inozyme Pharma
4.00
-0.60
-13.04%
ADAG
Adagene
1.85
-0.97
-34.40%
IVVD
Invivyd
0.74
-0.35
-32.11%

Clearside Biomedical Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Clearside Biomedical Approves Share Increase at Annual Meeting
Neutral
May 30, 2025

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025